These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 31143186)

  • 1. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
    Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
    Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
    Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
    J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Developed NK-92MI Cell Line with Siglec-7
    Huang CH; Liao YJ; Fan TH; Chiou TJ; Lin YH; Twu YC
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29617289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viewing Siglecs through the lens of tumor immunology.
    Fraschilla I; Pillai S
    Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
    Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
    Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells.
    Adeniji OS; Kuri-Cervantes L; Yu C; Xu Z; Ho M; Chew GM; Shikuma C; Tomescu C; George AF; Roan NR; Ndhlovu LC; Liu Q; Muthumani K; Weiner DB; Betts MR; Xiao H; Abdel-Mohsen M
    PLoS Pathog; 2021 Nov; 17(11):e1010034. PubMed ID: 34762717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
    Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
    Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
    Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
    mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.
    Hudak JE; Canham SM; Bertozzi CR
    Nat Chem Biol; 2014 Jan; 10(1):69-75. PubMed ID: 24292068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
    Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
    Blood Adv; 2022 Jun; 6(11):3352-3366. PubMed ID: 35294519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 13. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siglec and anti-Siglec therapies.
    Murugesan G; Weigle B; Crocker PR
    Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
    Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
    J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
    Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
    J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.